Success Stories: A Research Associate in the Field of Clinical Epidemiology Secured EB-1A Approval in Just 10 Days, Special Thanks to Premium Processing Service

Client’s Testimonial:

“Overall I am very satisfied with the service provided.”

On April 8^th, 2021, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Associate in the Field of Clinical Epidemiology (Approval Notice).

General Field: Clinical Epidemiology

Position at the Time of Case Filing: Research Associate

Country of Origin: India

Country of Residence at the Time of Filing: India

Approval Notice Date: April 8^th, 2021

Processing Time: 10 days (Premium Processing Requested)

Case Summary:

A research associate hired us to file an EB-1A (Alien of Extraordinary Ability) petition on his behalf. We started evaluating his credentials after his approach and noted that he is a holder of a Ph.D. in epidemiology and has many years of experience in clinical outcomes and health services research, which made him a perfect candidate to continue pursuing his research work in the field of clinical epidemiology. Our client’s EB-1A petition consisted of the following information:

Research Brief: We discovered our client’s research on chronic comorbidity type and their impact on diabetes care and how his other research work addresses some of our nation’s and the world’s most pressing issues, including the effects of socioeconomic factors on health outcomes, and role of palliative care in surgical patients. We concluded that his work is of the utmost significance due to its direct applicability in global efforts to address chronic health disparities and improve clinical outcomes..

Citation Count: We also recorded the 345 times his work has been cited by independent and leading researchers from prominent institutions around the world, at least in 35 countries, highlighting that his work has been highly recognized and widely executed.

Publication & Peer-Review Experience: We highlighted the 31 peer-reviewed scientific articles, published in some of the top-ranked journals in the field. Besides, we noted that he has assessed the work of his peers for remarkably acclaimed journals and professional conferences 180 times. Thus, conducting peer reviews for these distinct journals is a testament to his standing as a globally recognized expert in the field of clinical epidemiology.

To further support our client’s petition, we included recommendation letters obtained by him from 4 fellow experts, stating how our client’s work is vital. The following excerpts have been taken from two of the submitted letters:

“[Client’s] advanced data management techniques and his deep look at the connection between socioeconomic factors and treatment outcomes are representative of his critical place within the field of clinical epidemiology.”

“It is without hesitation that I declare he is a prolific and influential researcher. The healthcare sector overall and the health of millions, stand to benefit from [client’s]continued work in the United States.”

With over 17,000 approved cases, we have unprecedented expertise in handling I-140 petitions. When our client approached our law firm, we kept him updated about all the adjudicating trends of USCIS and accordingly customized his EB-1A petition. A big thanks to premium processing (PP) service, which is a paid option offered by the USCIS that allows petitioners to enjoy accelerated adjudication (the case will be processed within 15 days instead of 9-12 months).

Gladly, our client was able to achieve his EB-1A approval just in 10 days with the PP request. We are happy to be able to help our client and wish him well as he advances in his chosen path.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.